Nano Express

Nanoscale Research Letters

, Volume 4, Issue 3, pp 254-261

Open Access This content is freely available online to anyone, anywhere at any time.

Evaluation of Aerosol Delivery of Nanosuspension for Pre-clinical Pulmonary Drug Delivery

  • Po-Chang ChiangAffiliated withGlobal Research and Development, Pharmaceutical Research and Development, St. Louis Laboratories, Pfizer Inc Email author 
  • , Jason W. AlsupAffiliated withGlobal Research and Development, Pharmaceutical Research and Development, St. Louis Laboratories, Pfizer Inc
  • , Yurong LaiAffiliated withGlobal Research and Development, Pharmaceutical Research and Development, St. Louis Laboratories, Pfizer Inc
  • , Yiding HuAffiliated withGlobal Research and Development, Pharmaceutical Research and Development, St. Louis Laboratories, Pfizer Inc
  • , Bruce R. HeydeAffiliated withGlobal Research and Development, Pharmaceutical Research and Development, St. Louis Laboratories, Pfizer Inc
  • , David TungAffiliated withGlobal Research and Development, Pharmaceutical Research and Development, St. Louis Laboratories, Pfizer Inc Email author 

Abstract

Asthma and chronic obstructive pulmonary disease (COPD) are pulmonary diseases that are characterized by inflammatory cell infiltration, cytokine production, and airway hyper-reactivity. Most of the effector cells responsible for these pathologies reside in the lungs. One of the most direct ways to deliver drugs to the target cells is via the trachea. In a pre-clinical setting, this can be achieved via intratracheal (IT), intranasal (IN), or aerosol delivery in the desired animal model. In this study, we pioneered the aerosol delivery of a nanosuspension formulation in a rodent model. The efficiency of different dosing techniques and formulations to target the lungs were compared, and fluticasone was used as the model compound. For the aerosol particle size determination, a ten-stage cascade impactor was used. The mass median aerodynamic diameter (MMAD) was calculated based on the percent cumulative accumulation at each stage. Formulations with different particle size of fluticasone were made for evaluation. The compatibility of regular fluticasone suspension and nanosuspension for aerosol delivery was also investigated. The in vivo studies were conducted on mice with optimized setting. It was found that the aerosol delivery of fluticasone with nanosuspension was as efficient as intranasal (IN) dosing, and was able to achieve dose dependent lung deposition.

Keywords

Lung inflammation Intratracheal Intranasal Aerosol Particle size Pre-clinical Impactor Nano-suspension